A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to see how the different treatments compare to one another.
|Hyperlipidemia Dyslipidemia||Drug: torcetrapib/atorvastatin Drug: ezetimibe/simvastatin||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia.|
- Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.
- Changes in other lipid parameters and other biomarkers.
|Study Start Date:||January 2006|
|Study Completion Date:||January 2007|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00267267
Show 123 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|